drugset / Trial / NCT00872716

Quetiapine in Specific Phobia

NCT00872716

Phase 2 Completed 60 enrolled University Hospital Muenster AstraZeneca · collab
RandomizedParallel-groupQuadruple-blind

Summary

The study hypothesis is that quetiapine XR has anxiolytic properties. The study aims to investigate the putative anxiolytic properties of quetiapine XR in patients with anxiety disorders. Therefore, in a proof-of-concept design patients with simple phobia will be selected to investigate specific anxiolytic and antipanic activity during acute anxiety. Moreover, in a combined fMRI/visual stimulus presentation paradigm activity of fear-network associated brain structures such as the amygdala will be investigated under treatment with quetiapine XR or placebo. Additionally, genetic factors potentially mediating anxiolytic properties of quetiapine will be studied.

Timeline

Start
2009-04
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 100 mg

Indications